Combining Immunotherapies to Treat Liver Cancer
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with...
Progress Against Cancer
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with...
The FDA has approved the immunotherapeutic isatuximab-irfc (Sarclisa) to treat certain patients with multiple myeloma. The U.S. Food and...
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
The FDA has approved a targeted therapy for epithelioid sarcoma, the first treatment approved for this form of cancer....
The FDA has approved a molecularly targeted treatment for certain patients with this form of soft tissue sarcoma. The...
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has...
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted...
The FDA has approved a molecularly targeted therapeutic for patients with locally advanced or metastatic urothelial cancer. The U.S....
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. The...
The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The U.S....
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Today